目的 探讨microRNA-374b-5p对糖尿病增殖性视网膜病变(PDR)的作用。方法 回顾性研究2014-01至2014-07武警云南总队医院 2型糖尿病合并糖尿病视网膜病变(DR)的62例患者的相关资料。其中糖尿病非增殖性视网膜病变(NPDR)30例,PDR为32例,采集所有患者外周静脉血5 ml,测定其中microRNA-374b-5p及血管内皮生长因子(VEGF)含量,并进行相关性分析,同时将miR-374b-5p导入内皮细胞中检测VEGF表达情况及内皮细胞成血管能力的变化。结果 血清miR-374b-5p的测定结果发现,与NPDR组(7.993±6.194)比较,PDR组(4.308±3.313)表达下降明显,差异有统计学意义(P<0.05); 与NPDR组VEGF含量[(35.50±21.49)pg/ml]比较,PDR组[(74.64±26.57)pg/ml]显著性升高,差异有统计学意义(P<0.05)。miR-374b-5p与VEGF呈负相关性(R2=0.088,P=0.019)。PDR患者血清中miR-374b-5p含量下降而VEGF升高,两者呈负相关性。而miR-374b-5p导入内皮细胞后可抑制VEGF的mRNA及蛋白水平表达,同时抑制内皮细胞成血管能力。结论 PDR进展中miR-374b-5p下降,可导致其对抗VEGF表达升高能力下降,并诱发内皮细胞成血管增加,促进PDR发生和发展。
Abstract
Objective To explore the effect of microRNA-374b-5p on proliferative diabetic retinopathy. Methods Based on retrospective study, the peripheral blood of patients with diabetic non-proliferative (NPDR, n=30) and proliferative (PDR, n=32) retinopathy was collected, and the contents of microRNA-374b-5p and VEGF were determined, correlation analysis was performed at the same time, miR-374b-5p was introduced into endothelial cells to detect the expression of VEGF and the changes of endothelial cells' angiogenesis ability. Results Compared with NPDR group (7.993±6.194), the expression of serum miR-374b-5p in PDR group (4.308±3.313) decreased significantly (P<0.05). Compared with the content of VEGF in NPDR group [ (35.50±21.49)pg/ml], the content of VEGF in PDR group [((74.64±26.57)pg /ml] was significantly higher, and the difference was statistically significant (P<0.05). There was a negative correlation between miR-374b-5p and VEGF (R2=0.088, P=0.019). The level of miR-374b-5p in serum of PDR patients decreased and VEGF increased, which was negatively correlated with each other, while miR-374b-5p could inhibit the expression of VEGF mRNA and protein, and inhibit the angiogenesis ability of endothelial cells. Conclusions The decline of miR-374b-5 in the progress of PDR leads to a decline in its ability to resist the increase of VEGF expression, and induces an increase in endothelial cell angiogenesis, thereby promoting the occurrence and development of PDR.
关键词
糖尿病增殖性视网膜病变 /
microRNA /
血管内皮生长因子 /
内皮细胞 /
成血管
Key words
diabetic proliferative retinopathy /
microRNA /
vascular endothelial growth factor /
endothelial cells /
angiogenesis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults [J]. JAMA, 2013, 310(9): 948-959.
[2] Song P, Yu J, Chan K Y, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis [J]. J Glob Health, 2018, 8(1):10803.
[3] 王 鸿, 李晓静, 刘 佳, 等. 2型糖尿病患者血浆氧化三甲胺与视网膜病变的相关性 [J]. 武警医学, 2022, 33(8): 654-658.
[4] 张换想, 邱洪斌, 张艺潆. 糖尿病视网膜病变的危险因素[J]. 牡丹江医学院学报, 2022, 43(3): 64-68.
[5] Gong Q, Xie J, Liu Y, et al. Differentially expressed microRNAs in the development of early diabetic retinopathy [J]. J Diabetes Res, 2017, 2017: 4727942.
[6] Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the expert committee on the diagnosis and classification of diabetes mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization [J]. Diabetes Res Clin Pract, 1999, 44(1): 21-26.
[7] Chobanian A V, Bakris G L, Black H R, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure [J]. Hypertension, 2003, 42(6): 1206-1252.
[8] 李 瑞, 李万明, 陈小丽. 微小RNA-126和血管内皮生长因子在增殖性糖尿病视网膜病变患者视网膜前膜中的表达及意义 [J]. 实用临床医药杂志, 2022, 26(2): 1-5,10.
[9] 王 涛, 崔月玲, 王晓聪, 等. 糖尿病性视网膜病变患者血清microRNA-20a-5p、VEGF水平变化及其临床意义 [J]. 中国现代医学杂志, 2021, 31(21): 20-25.
[10] 李继红, 牛梦琦. 血管内皮生长因子水平对2型糖尿病患者并发视网膜微血管病变的预测价值 [J]. 实用医学杂志, 2022, 38(8): 1001-1005.
[11] Li E H, Huang Q Z, Li G C, et al. Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene [J]. Biosci Rep, 2017, 37(2):45-56.
[12] Mcarthur K, Feng B, Wu Y, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy [J]. Diabetes, 2011, 60(4): 1314-1323.
[13] Bartel D P. MicroRNAs: target recognition and regulatory functions [J]. Cell, 2009, 136(2): 215-233.
[14] Natarajan R, Putta S, Kato M. MicroRNAs and diabetic complications [J]. J Cardiovasc Transl Res, 2012, 5(4): 413-422.
[15] Singer M A, Kermany D S, Waters J, et al. Diabetic macular edema: it is more than just VEGF [J]. F1000 Res, 2016, 1:5.
PDF(1064 KB)
